VIEX Capital Advisors’s Enzo Biochem, Inc. ENZ Stock Holding History

VIEX Capital Advisors’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.98M	Sell	1,334,479 -202,378	-13%	-$489K	9.62%	4
2022 Q2	$3.18M	Buy	1,536,857 +101,727	+7%	+$252K	8.4%	4
2022 Q1	$4.16M	Sell	1,435,130 -300,957	-17%	-$966K	7.44%	5
2021 Q4	$5.57M	Buy	1,736,087 +225,686	+15%	+$770K	8.96%	5
2021 Q3	$5.35M	Buy	1,510,401 +11,499	+0.8%	+$38.4K	3.24%	8
2021 Q2	$4.75M	Buy	+1,498,902	New	+$4.71M	3.4%	6
2021 Q1	–	Sell	-155,481	Closed	-$392K	–	12
2020 Q4	$392K	Buy	+155,481	New	+$339K	0.32%	7

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VIEX Capital Advisors's ENZ Position: Q3 2022 in Review

VIEX Capital Advisors reduced its Enzo Biochem, Inc. (ENZ) stake by 13% in Q3 2022, selling an estimated $489K and leaving 1,334,479 shares worth $2.98M. The position accounts for 9.62% of the portfolio, ranked #4.

VIEX Capital Advisors first reported a position in ENZ in Q4 2020 and has held it in 7 quarters since. The position peaked at $5.57M in Q4 2021. 49 funds tracked by Wall St. Rank hold ENZ as of Q3 2022.

VIEX Capital Advisors held 1,334,479 shares of Enzo Biochem, Inc. worth $2.98M as of Q3 2022.
VIEX Capital Advisors sold 202,378 Enzo Biochem, Inc. shares in Q3 2022, an estimated $489K.
Enzo Biochem, Inc. made up 9.62% of VIEX Capital Advisors's portfolio in Q3 2022, its #4 holding.
VIEX Capital Advisors first reported a position in Enzo Biochem, Inc. in Q4 2020 and has held it in 7 quarters since.
VIEX Capital Advisors's Enzo Biochem, Inc. position peaked at $5.57M in Q4 2021.
49 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2022.

Based on VIEX Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.